Medium-chain acyl CoA dehydrogenase (MCAD) (acylCoA: (acceptor) 2,3-oxidoreductase, EC 1.3.99.3) deficiency in two patients, MY and AH, was examined by use of an anti-MCAD antibody and the cDNA for the enzyme. No MC AD protein was detected by immunoblot analysis in the fibroblast extract from the first patient MY, while it was present. but not catalytically active in the second patient AH. In order to clarify the molecular mechanism of these deficiencies, a cDNA encoding MCAD was isolated from a human placenta cDNA library. The cDNA contained 1.263 nucleotides of the coding region, 64 nuc1eotides of the 5'-noncoding region, and 686 nucleotides of the 3'-noncoding region. The level of mRNA for MC AD in the patients was examined by RNA blot analysis with the cDNA as probe, and the results indicate that the patient MY also had the mRNA and that the level of the mRNA in both patients was almost the same as that of the control subject. Thus it seems that the deficiency in the patients is due to a point mutation(s) and that the position of the mutation(s) in the gene of patient MY is different from that of patient AH.
2 than 85 patients [1, 2J since its first identification in 1982 [3] . The clinical signs of MCAD deficiency are variable. It has been described that in patients sudden infant death syndrome, recurrent Reye"s syndrome, and episodic hypoglycemic coma develop after fasting with absence of frank ketosis [2] . The causes of the phenotypic heterogeneity in MCAD deficiency are still unknown. [ 35 SJMethionine labelling/immunoprecipitation analysis suggested that MC AD deficiency in 13 patients was due to a point mutation(s) of the gene that affected the catalytic activity of the enzyme [4] . Recently, partial cDNAs encoding MC AD have been isolated from human liver [5, 61 and placenta [61 cDNA libraries. and a cDNA for the enzyme has also been obtained from a rat liver cDNA library [7, 8J. In the present study, we isolated a full-length cDN A encoding MC AD from a human placenta cDNA library. By using this cDNA and an anti-MC AD antibody, we analyzed the mode of MC AD deficiency in two patients and found that both patients have mRNA for the enzyme but that one of them does not contain enzyme protein, indicating that they have different kinds of MCAD deficiency.
MATERIALS AND METHODS

Materials.
Enzymes for DNA manipulation, MI3 sequencing kit. and Random Primer DNA Labeling Kit were purchased from Takara Shuzo Co., Ltd., Kyoto; horseradish peroxidase-conjugated goat anti-rabbit IgG, from Bio-Rad Laboratories, Richmond, CA; dCTP and diaminobenzidine (DAB) enhancement kit. from Amersham International, Buckinghamshire, UK; and acyl CoAs. from Sigma Chemical Company, St. Louis, MO. Anti-pig kidney MC AD antiserum was prepared as described previously [9] .
Cell culture. Skin fibroblasts were taken from patients referred to as AH and MY, and those taken from a normal individual were kindly donated by Dr. Y. Nozawa of Gifu University. Details of the clinical features of patient MY have been reported elsewhere [10] . Fibroblasts were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum. Monolayers were harvested by trypsinization, washed three times with phosphate-buffered salt solution (without magnesium and calcium), and used for the experiments.
Preparation of extracts of fibroblasts. Fibroblasts (2 X 10 6 cells) were suspended in 100,u1 of 10 mM Tris-HCI buffer (pH 7.5) containing I mM EDTA. The suspension was sonicated for 30 s at 10 watts in an ice bath and centrifuged at 10.000 X g for 10 mi n at 4T. The su pernatant was used as the extract.
Assay of MCAD activity. Fifty microliters of the extract of fibroblasts was incubated with I ,ul of the anti-MC AD antiserum or normal rabbit serum at 4 C overnight. Fifty microliters of Protein A-Sepharose suspension (100 mg/ml) was then added to the mixture and incubated for 2 h at 4T. After centrifugation for I min at 800 X g, MC AD activity in the supernatant was assayed by the phenazine methosulfate (1.5 mM)/dichlorophenolindophenol (DCIP) (0.048 mM) method 3 [11] . Net MC AD activity was expressed as the value suppressed by the addition of the antibody.
Isolation and sequencing of cDNA for human placenta MCAD. cDNAs for MCAD were isolated by immunoscreening of a human placenta cDNA library constructed in ,lgt I1 (Clontech Laboratories, lnC., Palo Alto, CA) according to the method of Young and Davis [12J, as described previously [8] . EcoRI fragments of the cDNA were ligated into the EcoRI site of pUC 19, and deletion mutants of a subcloned pUC 19 plasmid were prepared by digestion with exonuclease III and mUilg bean nuclease [13] . The DNA sequence of the deleted inserts was determined by the dideoxy chain termination method [14j. Analysis of sequence data was performed by use of the GENETYX programs (SDC, Tokyo).
RNA blot analysis. RN As were isolated from fibroblasts of the patients A H and MY and the control subject by the guanidinium thiocyanate extraction method described by Chirgwin et al. [IS] . The MCAD probe, a Hapll-Hindlll fragment of the cDNA, was radiolabeled with a Random Primer DNA Labeling Kit. For RNA dot blot analysis, the RNA samples were dissolved in 50% formamide and 6% formaldehyde. incubated for I h at SOT to denature the RNA, and then chilled in ice. After the samples had been spotted directly onto a GeneScreen Plus membrane (DuPont Co., Boston, MA), the membrane was incubated overnight at 60C with the 32P-labeled MC AD probe in 10% dextran sulfate. 1% sodium dodecyl sulfate (SDS), and I M NaCI. After washing with 2 X SSC (I X SSC, 0.15 M NaCI-0.015 M sodium citrate) containing 1% SDS four times at 25T, the membrane was exposed to an X-ray film for 2-6 days at -80'C, Immunoblotting analysis. The fibroblast extracts (10111) were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting [16] . The membrane was stained with 50 mM Tris-HCI buffer (pH 7.5) containing 2 mgjml of DAB tetrahydrochloride and 0.02% H 2 0 2 . Then the membrane was washed three times for 5 min each time with 10 mM Tris-HCI (pH 7.5) containing 0.15 M NaCI and then dried. DAB on the membrane was amplified by use of a DAB enhancement kit.
Protein concentration. Protein content was determined according to the method of Smith et al. [17J with bovine serum albumin used as the standard.
RESULTS AND DISCUSSION
MCA D act/Vlty in fibroblasts from patients
Dehydrogenase activities toward acyl CoA compounds were measured in fibroblasts from MCAD deficient patients. The enzyme activity measured with octanoyl CoA as substrate in extracts of fibroblasts from the MC AD-deficient patients was 10-15 unitsjmg protein. However, this activity was not abolished by treatment of the extracts with the anti-MC AD antiserum, indicating that the observed activity cannot be ascribed to MC AD. In contrast, the enzyme activity of the fibroblasts of the normal subject was 15-22 unitsjmg which is 50-60% of the control level. This decrease can be ascribed to the fact that MC AD has a substantial activity toward short-chain acyl CoAs [18. 19] .
The higher MC AD activity in our data as compared with that given in other reports [2. 3. 101 might be due to different assay cond itions. Figure I shows the immunoblot analysis of MCAD protein for extracts of the fibroblasts from the patients and the control. MC AD proteins were detectable in the control (lane Cl and patient AH fibroblasts (lane B). The molecular weight of the protein in patient AH was the same as that in the control. suggesting that the deficiency in patient AH is due to a point mutation(s) affecting the enzymatic activity. In contrast. the enzyme protein was not detected in patient MY fibroblasts (lane A).
Immunoblot analysis
Isolation and sequencing of cDNA for human placenta MeA D
For DNA and RNA hybridization analyses, we isolated cDNAs encoding MC AD from a human placenta cDNA library. One (HMC AD-5) of them contained 64 nucleotides of the 5' noncoding region, 1.263 nucleotides of the coding region, and 686 nucleotides of the 3' noncoding region. as shown in Fig. 2 . Figure  3 shows the nucleotide sequence of the cDNA (HMC AD-5). The first ATG codon was located at n ucleotides 11-13, but the termi nal cod on appeared at n uc leotides 23-25. This reading frame codes 4 amino acid residues. cDNAs in which the first initiation codon is followed by a stop codon upstream from the second initiation codon have been reported for porcine o-amino acid oxidase [20] and for rat 3-oxoacyl CoA thiolase [21] . The second A TG codon was located at nucleotides 65-67 and the terminal codon, TAA, at nucleotides l,328-l,330. The 1,263-nucleotide reading frame was completely identical with that of Kelly et al. [6] , although a minute difference was found in 5' noncoding region.
RNA blot analysis
In order to estimate the level of mRN A for MC A D in the patients, we carried out RNA dot blot analysis with the 32P-labeled HapIl-HindIII fragment of the cDNA as a hybridization probe. As shown in Fig. 4 , the fibroblasts from both patients prod uced the same level of mRN A as that of the control. All these results indicate that patient MY is different from patient AH in the mode of the deficiency. Although both patients have mRNA for MCAD at the same level as that of the control, patient MY does not possess immunologically detectable MCAD protein. This finding indicates that in patient MY the enzyme protein is not produced or, if produced, is somehow aberrant. If the protein is not synthesized at all in this patient, the mutation would seem to occur in the 5' noncoding region of the mRN A or in the coding region containing the initiation codon, resulting in a failure of translation. If the protein is synthesized, it would seem that patient MY synthesizes an abnormal precursor of MCAD which is susceptible to digestion by protease(s) or an unstable enzyme. In a recent preliminary report [22] , a patient with MC A D deficiency had an abnormal 5' noncoding region of the gene, which resulted in a failure of mitochondrial uptake of the precursor. However, in the case of our patient AH. the point mutation(s) might have occurred in the coding region of the gene, resulting in the production of a catalytically inactive enzyme. The detailed structures of the mRNAs from these and lower dots. 1.75 f.l g. patients are currently under investigation in our laboratory.
